However, ALK L1196M, a gatekeeper mutation that leads to resistance to crizotinib, showed little prevalence between tumor DNA and ctDNA (2% versus 22%, P=0.008), which implies that ctDNA can predict ALK-TKI resistance sometimes. The gene discussed is ALK; the disease is neoplasm.